Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2022 | 03-2022 | 12-2021 | 09-2021 | 06-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 24,548 | 40,202 | 27,605 | 38,884 | 13,386 |
| TOTAL | $32,414 | $43,584 | $32,714 | $45,235 | $18,534 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 19 | 17 | 15 | 16 | 13 |
| TOTAL | $19 | $17 | $15 | $16 | $13 |
| Total Assets | $32,433 | $43,601 | $32,729 | $45,250 | $18,547 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,078 | 4,311 | 3,687 | 5,559 | 6,268 |
| Accrued Expenses | 3,984 | 4,467 | 2,844 | 3,150 | 2,640 |
| Other current liabilities | 19 | 2,614 | 4,874 | 27,545 | 48,720 |
| TOTAL | $7,081 | $11,392 | $11,923 | $36,769 | $57,802 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | 520 | N/A | N/A | 513 |
| TOTAL | $N/A | $520 | $N/A | $N/A | $513 |
| Total Liabilities | $7,081 | $11,912 | $11,923 | $36,769 | $58,314 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 6,764 | 6,664 | 6,664 | 5,881 | 4,860 |
| Common Shares | 67 | 67 | 59 | 55 | 49 |
| Retained earnings | -203,673 | -196,691 | -183,243 | -152,836 | -115,786 |
| TOTAL | $25,352 | $31,689 | $20,806 | $8,481 | $-39,767 |
| Total Liabilities And Equity | $32,433 | $43,601 | $32,729 | $45,250 | $18,547 |